EA200301152A1 - Жидкая фармацевтическая композиция - Google Patents

Жидкая фармацевтическая композиция

Info

Publication number
EA200301152A1
EA200301152A1 EA200301152A EA200301152A EA200301152A1 EA 200301152 A1 EA200301152 A1 EA 200301152A1 EA 200301152 A EA200301152 A EA 200301152A EA 200301152 A EA200301152 A EA 200301152A EA 200301152 A1 EA200301152 A1 EA 200301152A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pain
pharmaceutical composition
component
liquid pharmaceutical
polyhydric alcohol
Prior art date
Application number
EA200301152A
Other languages
English (en)
Other versions
EA008087B1 (ru
Inventor
Неема Махеш Кулкарни
Майкл Шнайдер
Стивен Бернард Силберинг
Ханс Ричард Мэйер-Уоннэй
Нахид Саний-Яхиай
Original Assignee
Уорнер-Ламберт Компани Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200301152(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уорнер-Ламберт Компани Ллс filed Critical Уорнер-Ламберт Компани Ллс
Publication of EA200301152A1 publication Critical patent/EA200301152A1/ru
Publication of EA008087B1 publication Critical patent/EA008087B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Описаны жидкая фармацевтическая композиция на основе аналога ГАМК, включающая по меньшей мере один многоатомный спирт, содержащий от 2 до 6 атомов углерода, имеющая pH приблизительно от 5,5 до 7,0, и, кроме того, двухкомпонентная жидкая фармацевтическая композиция, содержащая первый компонент, включающий порошкообразную смесь, включающую аналог ГАМК и твердый многоатомный спирт, и второй компонент, включающий жидкую основу, а также способы получения композиций и способ лечения церебральных заболеваний, включающих эпилепсию, приступы обморока, гипокинезию и черепные травмы, нейродегенеративные расстройства, депрессию, маниакальные и биполярные расстройства, беспокойство, панику, воспаление, почечную колику, бессонницу, желудочно-кишечное повреждение, невоздержанность, боль, включая нейропатическую боль, мышечную боль, скелетную боль и мигрень, с использованием терапевтически эффективного количества фармацевтических композиций.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200301152A 2001-05-25 2002-04-29 Жидкая фармацевтическая композиция EA008087B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25
PCT/IB2002/001500 WO2002094220A1 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Publications (2)

Publication Number Publication Date
EA200301152A1 true EA200301152A1 (ru) 2004-04-29
EA008087B1 EA008087B1 (ru) 2007-02-27

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301152A EA008087B1 (ru) 2001-05-25 2002-04-29 Жидкая фармацевтическая композиция

Country Status (43)

Country Link
US (2) US20020198261A1 (ru)
EP (1) EP1395242B1 (ru)
JP (1) JP2004534764A (ru)
KR (1) KR100582963B1 (ru)
CN (1) CN100346779C (ru)
AP (1) AP1815A (ru)
AR (1) AR033922A1 (ru)
AT (1) ATE334656T1 (ru)
AU (1) AU2002258026B2 (ru)
BG (1) BG108376A (ru)
BR (1) BR0209973A (ru)
CA (1) CA2446574C (ru)
CR (1) CR7150A (ru)
CY (1) CY1105147T1 (ru)
CZ (1) CZ299755B6 (ru)
DE (1) DE60213592T2 (ru)
DK (1) DK1395242T3 (ru)
DO (1) DOP2002000403A (ru)
EA (1) EA008087B1 (ru)
EE (1) EE200300587A (ru)
EG (1) EG24078A (ru)
ES (1) ES2265040T3 (ru)
GE (1) GEP20053620B (ru)
HR (1) HRP20030833B1 (ru)
HU (1) HUP0401366A2 (ru)
IL (1) IL158359A0 (ru)
IS (1) IS2428B (ru)
MA (1) MA27026A1 (ru)
MX (1) MXPA03009392A (ru)
MY (1) MY128615A (ru)
NO (1) NO20035200L (ru)
NZ (1) NZ529173A (ru)
OA (1) OA12604A (ru)
PA (1) PA8545901A1 (ru)
PE (1) PE20030087A1 (ru)
PL (1) PL366384A1 (ru)
PT (1) PT1395242E (ru)
RS (1) RS87203A (ru)
SI (1) SI1395242T1 (ru)
SK (1) SK286227B6 (ru)
SV (1) SV2003001053A (ru)
WO (1) WO2002094220A1 (ru)
ZA (1) ZA200308393B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2004016260A1 (en) * 2002-08-15 2004-02-26 Pfizer Limited Therapeutic use of fused bicyclic or tricyclic amino acids
BR0317253A (pt) * 2002-12-13 2005-11-01 Warner Lambert Co Derivados pregabalina para o tratamento da fibromialgia e outras patologias
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
NZ545494A (en) * 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
ATE526988T1 (de) * 2003-10-08 2011-10-15 Mallinckrodt Llc Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
WO2006041158A1 (ja) * 2004-10-14 2006-04-20 Daikin Industries, Ltd. 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
WO2007017510A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Isophthalsäurediamide zur behandlung der alzheimer erkrankung
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
JP2010043063A (ja) * 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2923694B1 (en) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
GB2591389A (en) 2018-08-18 2021-07-28 Ftf Pharma Private Ltd Pharmaceuticals solution for oral dosage
WO2020039264A2 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
DK3946260T3 (da) 2019-03-26 2026-03-23 Orion Corp Pregabalinformuleringer og anvendelse deraf
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
AU2022210856A1 (en) 2021-01-22 2023-08-17 Egis Gyógyszergyár Zrt. Topical formulation containing modified phospholipid compounds
JPWO2022168968A1 (ru) * 2021-02-05 2022-08-11
WO2023034269A1 (en) * 2021-08-31 2023-03-09 Avion Pharmaceuticals, Llc Stable gabapentin powder
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
ATE271864T1 (de) * 1998-05-15 2004-08-15 Warner Lambert Co Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
BR0115783A (pt) * 2000-11-30 2003-09-16 Pfizer Prod Inc Combinação de agonistas de gaba e inibidores de sorbitol desidrogenase

Also Published As

Publication number Publication date
KR100582963B1 (ko) 2006-05-24
DE60213592D1 (de) 2006-09-14
CN100346779C (zh) 2007-11-07
US20040072904A1 (en) 2004-04-15
NZ529173A (en) 2005-07-29
EG24078A (en) 2008-05-11
AP2003002907A0 (en) 2003-12-31
DOP2002000403A (es) 2002-11-30
HRP20030833B1 (en) 2007-04-30
ATE334656T1 (de) 2006-08-15
IS2428B (is) 2008-10-15
WO2002094220A1 (en) 2002-11-28
AR033922A1 (es) 2004-01-07
MY128615A (en) 2007-02-28
CN1509165A (zh) 2004-06-30
EP1395242A1 (en) 2004-03-10
CR7150A (es) 2004-02-23
US7256216B2 (en) 2007-08-14
CA2446574C (en) 2008-04-01
IS6986A (is) 2003-10-09
SK286227B6 (sk) 2008-05-06
JP2004534764A (ja) 2004-11-18
CY1105147T1 (el) 2010-03-03
US20020198261A1 (en) 2002-12-26
ES2265040T3 (es) 2007-02-01
AU2002258026B2 (en) 2007-08-02
PE20030087A1 (es) 2003-02-14
IL158359A0 (en) 2004-05-12
PL366384A1 (en) 2005-01-24
RS87203A (sr) 2006-10-27
NO20035200D0 (no) 2003-11-24
NO20035200L (no) 2003-11-24
CZ299755B6 (cs) 2008-11-12
DE60213592T2 (de) 2007-08-09
PA8545901A1 (es) 2003-09-05
MA27026A1 (fr) 2004-12-20
KR20040003006A (ko) 2004-01-07
HUP0401366A2 (hu) 2004-11-29
EP1395242B1 (en) 2006-08-02
DK1395242T3 (da) 2006-10-30
HRP20030833A2 (en) 2004-08-31
EE200300587A (et) 2004-02-16
BG108376A (bg) 2005-04-30
BR0209973A (pt) 2004-04-06
SV2003001053A (es) 2003-03-18
GEP20053620B (en) 2005-09-26
HK1062646A1 (zh) 2004-11-19
ZA200308393B (en) 2005-04-26
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
AP1815A (en) 2008-01-04
OA12604A (en) 2006-06-08
CA2446574A1 (en) 2002-11-28
SI1395242T1 (en) 2006-10-31
SK14112003A3 (sk) 2004-08-03
EA008087B1 (ru) 2007-02-27
CZ20033066A3 (cs) 2004-08-18

Similar Documents

Publication Publication Date Title
EA200301152A1 (ru) Жидкая фармацевтическая композиция
UA49011C2 (ru) Translated By PlajПРОИЗВОДНЫЕ ЦИКЛИЧЕСКОЙ АМИНОКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
EA200200293A1 (ru) Бициклические аминокислоты в качестве фармацевтических агентов
CA2322558A1 (en) Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
EA199800682A1 (ru) Производные циклической аминокислоты или их фармацевтически приемлемые соли, фармацевтическая композиция и способ лечения депрессии, состояний паники, страха и болевых ощущений
NZ503651A (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
RU94042240A (ru) Антагонисты рецепторов возбужденных аминокислот, способ получения, промежуточные соединения, фармацевтическая композиция
EA200401127A1 (ru) АМИНОКИСЛОТЫ С АФФИННОСТЬЮ К α2δ-БЕЛКУ
EA200500007A1 (ru) Пролекарства возбуждающих аминокислот
EA200101134A1 (ru) Одно- и двузамещенные 3-пропил-гамма-аминомасляные кислоты
EA200300854A1 (ru) Применение обратных агонистов гамка в комбинации с частичными агонистами никотиновых рецепторов, эстрогеном, избирательными модуляторами эстрогена или витамином е для лечения познавательных расстройств
MX2010013523A (es) Sales novedosas de acido (4{[(5-{[(3-clorofenil)metil]oxi}-2-metil fenil)carbonil]amino}-3-metilfenil)acetico.
ATE339205T1 (de) (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen
JPH10506407A (ja) 睡眠の誘導方法
UY26475A1 (es) Método novedoso para la sintesis estereoselectiva de aminoácidos cíclicos.
ATE289583T1 (de) Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
KR102269493B1 (ko) (r)-디미라세탐 (1) 및 (s)-디미라세탐 (2)을 비-라세미 비로 포함하는 상승작용적 조성물
IL120006A0 (en) Valnoctamide stereoisomers a method for their separation and uses thereof
BR9607443A (pt) Composto de 4-aminotetraidrobenzisoxazol ou-isatiazol composição farmacêutica e utilização do composto
BG101929A (en) Benzamides for neurodegenerative disorder treatment
ECSP034853A (es) Composición farmacéutica líquida
ATE283838T1 (de) Wirksame derivate der valproinsäure zur behandlung von neurologischen und psychotischen störungen, und ein verfahren zu ihrer herstellung
UY27310A1 (es) Composición farmacéutica líquida
JP2002528387A (ja) 脂肪酸誘導体
EA200600230A1 (ru) Способ получения хирально чистого n-(транс-4-изопропилциклогексилкарбонил)-d-фенилаланина и его кристаллических модификаций

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ KG MD TJ TM